{"id":545184,"date":"2025-07-02T19:00:50","date_gmt":"2025-07-02T19:00:50","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/545184\/parkinsons-disease-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-annovis-bio-cerevel-therapeutics-roche.html"},"modified":"2025-07-02T19:00:50","modified_gmt":"2025-07-02T19:00:50","slug":"parkinsons-disease-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-annovis-bio-cerevel-therapeutics-roche","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/545184\/parkinsons-disease-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-annovis-bio-cerevel-therapeutics-roche.html","title":{"rendered":"Parkinson’s Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Annovis Bio, Cerevel Therapeutics, Roche,"},"content":{"rendered":"
\n
\"Parkinson's<\/a><\/div>\n
\n
Parkinson’s Disease Pipeline Insights<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cParkinson\u2019s Disease- Pipeline Insight, 2025\u201d report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson\u2019s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

According to DelveInsight, over 130 prominent companies are actively involved in developing more than 150 therapeutic candidates for the treatment of Parkinson’s disease.<\/p>\n

Parkinson’s Disease Overview:<\/p>\n

Parkinson’s disease (PD) is a chronic and progressive neurological condition that primarily impairs movement due to the degeneration of dopamine-producing neurons in the substantia nigra, a brain region essential for motor control. It usually affects individuals over the age of 60, though it can appear earlier, and is the second most prevalent neurodegenerative disorder after Alzheimer’s disease. Symptoms differ significantly between individuals and are often challenging to predict or manage.<\/p>\n

Motor symptoms typically include tremors, muscle stiffness, slowed movement (bradykinesia), and impaired balance, increasing the risk of falls. In addition, non-motor symptoms such as sleep disturbances, depression, anxiety, and cognitive decline are frequently observed.<\/p>\n

The exact cause of PD remains unknown, but both genetic mutations (such as in the LRRK2 and SNCA genes) and environmental exposures (like pesticides or heavy metals) are believed to play a role. On a cellular level, PD is marked by the buildup of alpha-synuclein protein within Lewy bodies and a shortage of dopamine, which disrupts normal neurotransmitter activity. Diagnosis is primarily clinical but may be supported by imaging tools like DaTscan.<\/p>\n

While there is no cure, treatment aims to control symptoms. Levodopa is the most commonly used drug, often combined with dopamine agonists and MAO-B inhibitors. In more advanced stages, deep brain stimulation (DBS) may offer additional relief. Supportive therapies such as physical and occupational therapy, along with lifestyle modifications, are essential for maintaining quality of life.<\/p>\n

Request for a detailed insights report on Parkinson’s Disease pipeline insights<\/a><\/strong><\/p>\n

“Parkinson’s Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson’s Disease Therapeutics Market.<\/p>\n

Key Takeaways from the Parkinson’s Disease Pipeline Report<\/strong><\/p>\n